magnesium sulfate; potassium chloride; sodium sulfate · Azurity · NDA 213135
Sutab
Earliest generic entry, as listed
4 Aug 2037
Blocked by patent: US 10143656, US 11033498, US 11382864, US 11638697.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10143656 | product | 4 Aug 2037 |
| US 11033498 | use U-3164 | 4 Aug 2037 |
| US 11382864 | use U-3164 | 4 Aug 2037 |
| US 11638697 | product | 4 Aug 2037 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026First generic approved · 213135-00128 May 2026
- 25 Oct 2026Generic approved · 213135-00128 May 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213135 · 001 · RLD | tablet, oral | 0.225GM;0.188GM;1.479GM | 4 Aug 2037 |